News|Articles|October 4, 2026

FAQ: What clinicians need to know about OCU410 phase 2 ArMaDa results

Author(s)Kassi Filkins, Veeral S. Sheth, MD, MBA, FACS, FASRS

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

One subretinal injection of medium-dose OCU410 (AAV5-hRORA; Ocugen) reduced geographic atrophy (GA) lesion growth by 32.3% compared with untreated controls at 12 months (nominal P = .0353) in the randomized phase 2 portion of the phase 1/2 ArMaDa trial (NCT06018558), according to data Raj K. Maturi, MD, presented at the Retina Society 2026 annual meeting in Los Angeles.^1,2

Related to this article

October 19th, 2026

Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA

Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.

October 24th, 2026

AAO 2026: GLP-1RA initiation not linked to anti-VEGF burden in DME

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

October 24th, 2026

Teprotumumab and TED: Sarah Cheng, MD, PhD, on orbital tissue changes

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.

(Image credit: Modern Retina; Christina Weng; Amer Alsoudi; Monia Reding) The Retina TL;DR with Dr. Weng: Thriving in retina fellowship with Amer Alsoudi, MD, and Monia Reding, MD

October 23rd, 2026

The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD

In the latest episode of The Retina TL;DR with Dr. Weng—Part 2 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two more of her former residents for candid advice on transitioning into fellowship, balancing research and family, and what excites them most about the future of retina.